drugset / Trial / NCT06198907
Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)
Phase 2
Not yet recruiting
69 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Dizal Pharmaceuticals · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in combination with sintilimab as the front-line treatment for patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC)
Timeline
- Start
- 2024-01
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golidocitinib | Small molecule | — | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |
| Background | Pemetrexed | Small molecule | — | Intravenous |